Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. Show more

Location: 7 Times Square, New York, NY, 10036, United States | Website: https://dianthustx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

645.1M

52 Wk Range

$13.37 - $32.27

Previous Close

$20.61

Open

$20.49

Volume

283,457

Day Range

$19.76 - $20.80

Enterprise Value

337.3M

Cash

263.2M

Avg Qtr Burn

-22.72M

Insider Ownership

7.87%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.